Total Skin and Beauty Dermatology Center | Birmingham, AL

Research site

(Unclaimed)

Location

2100 16th Avenue South Suite 202, Birmingham, Alabama, United States of America

Site insights

Top conditions

Top treatments

CTP-543

BMS-986165

Risankizumab

LIPO-202

IDP-110

HTU-520

Upadacitinib

Amlitelimab

BOTOX

Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 20 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting

Plaque Psoriasis

Drug: TAK-279

Drug: Placebo

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence (MMP US P3 416)

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower fac...

Active, not recruiting

Masseter Muscle Prominence

Drug: Placebo

Drug: BOTOX

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and saf...

Active, not recruiting

Alopecia Areata

Drug: Placebo

Drug: Amlitelimab

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Active, not recruiting

Alopecia Areata

Drug: Upadacitinib

Drug: Placebo

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) (IMMpactful)

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Active, not recruiting

Moderate Plaque Psoriasis

Drug: Risankizumab

Drug: Deucravacitinib

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting

Alopecia Areata

Drug: CTP-543

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting

Psoriasis

Drug: BMS-986165

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (VISIBLE)

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting

Scalp Psoriasis

Plaque Psoriasis

Drug: Placebo

Drug: Guselkumab